Cybin Inc., a clinical-stage pharmaceutical company focused on developing next-generation mental health treatments, announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The company expects its common shares to cease trading on NYSE American at market close on January 4, 2026, and begin trading on Nasdaq at market open on January 5, 2026, under the new ticker symbol HELP. Cybin will maintain its listing on Cboe Canada, where it will also trade under the HELP ticker beginning January 5, 2026.
The ticker symbol change to HELP directly reflects Cybin's mission to revolutionize mental healthcare by developing innovative treatment options for the large unmet needs in mental health conditions. This strategic move to Nasdaq, a premier exchange for technology and growth companies, signals Cybin's maturation as a late-stage neuropsychiatry company and could enhance its visibility among institutional investors and analysts who closely follow the biotechnology and pharmaceutical sectors. The transition represents a significant corporate milestone that typically accompanies increased market recognition and potentially greater liquidity for shareholders.
Cybin's clinical development pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This compound has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to address serious conditions where current therapies are inadequate. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder, along with a research pipeline of investigational compounds focused on 5-HT receptors.
The listing transfer comes as Cybin advances its clinical programs with promising data that could change the mental health treatment landscape through novel drugs designed to provide effective and durable results for patients. For business and technology leaders monitoring the intersection of biotechnology and mental health innovation, Cybin's Nasdaq listing represents more than an administrative change—it signifies the growing institutional recognition of psychedelic-inspired therapeutics as a legitimate and potentially transformative approach to addressing the global mental health crisis. The company's operational presence across Canada, the United States, the United Kingdom, and Ireland positions it to leverage international regulatory pathways and market opportunities.
Investors can access the latest news and updates relating to Cybin in the company's newsroom at https://ibn.fm/CYBN. The full press release detailing the listing transfer is available at https://ibn.fm/pcrpA.
